Ceritinib
Anaplastic Lymphoma Kinase (Alk) Inhibitors
Sold as Zykadia
- Drug class
- Anaplastic Lymphoma Kinase (Alk) Inhibitors
- Availability
- See label
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 4
Overview
Ceritinib is an active pharmaceutical ingredient in the Anaplastic Lymphoma Kinase (Alk) Inhibitors group (L01ED). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 2 | May 29, 2026 |
| EU European Union | EMA | 1 | January 29, 2026 |
| CA Canada | Health Canada | 1 | December 31, 2025 |
GBUnited Kingdom· MHRA
2 products
Uses
Zykadia as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). Zykadia as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.
How to take
EUEuropean Union· EMA
1 product
Uses
Zykadia as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). Zykadia as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.
How to take
CACanada· Health Canada
1 product
Uses
1. of the PM Guidance) or subsections that are not applicable at the time of the preparation of the most recent authorized product monograph are not listed. Recent Major Label Changes...................................................................................................
2 Table of Contents ................................................................................................................... 2 Part 1: Healthcare Professional Information ...........................................................................
4 1 Indications ....................................................................................................................... 4 2 Contraindications ............................................................................................................
4 3 Serious Warnings and Precautions Box ............................................................................ 4 4 Dosage and Administration .............................................................................................
Drug interactions
Known interactions involving Ceritinib. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 582. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB001011206 · revised May 22, 2026
- [2]European Medicines Agency · EMEA/H/C/003819 · revised January 29, 2026
- [3]Health Canada (DPD) · 02436779 · revised December 31, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.